دورية أكاديمية
The GLP-1 receptor agonists: what's all the (cardiovascular) hype about?
| العنوان: | The GLP-1 receptor agonists: what's all the (cardiovascular) hype about? |
|---|---|
| المؤلفون: | Taylor, J.1 jessica.taylor@uct.ac.za, Mpofu, R.1, Blockman, M.1 |
| المصدر: | SA Pharmaceutical Journal Incorporating Pharmacy Management. Jan/Feb2023, Vol. 90 Issue 1, p18-21. 3p. |
| مصطلحات موضوعية: | *GLUCAGON-like peptide-1 agonists, *GLUCAGON-like peptide-1 receptor, *PEOPLE with diabetes, *CARDIOVASCULAR diseases |
| مصطلحات جغرافية: | SOUTH Africa |
| مستخلص: | Over four million people in South Africa are estimated to have diabetes. People diagnosed with diabetes have an increased risk of developing cardiovascular disease. Safety trials conducted on novel hypoglycaemic agents suggest that glucagon-like peptide-1 receptor agonists may afford cardiovascular benefits in this at-risk population. Selection of an agent from this class, as add-on treatment to metformin, should be individualised and based on accessibility, affordability, convenience of the dosing schedule, and tolerability. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
| ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 162613022 1326 6 Academic Journal academicJournal 1325.62512207031 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=162613022&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => The GLP-1 receptor agonists: what's all the (cardiovascular) hype about?
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Taylor%2C+J%2E%22">Taylor, J.</searchLink><relatesTo>1</relatesTo><i> jessica.taylor@uct.ac.za</i><br /><searchLink fieldCode="AR" term="%22Mpofu%2C+R%2E%22">Mpofu, R.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Blockman%2C+M%2E%22">Blockman, M.</searchLink><relatesTo>1</relatesTo> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22SA+Pharmaceutical+Journal+Incorporating+Pharmacy+Management%22">SA Pharmaceutical Journal Incorporating Pharmacy Management</searchLink>. Jan/Feb2023, Vol. 90 Issue 1, p18-21. 3p. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22GLUCAGON-like+peptide-1+agonists%22">GLUCAGON-like peptide-1 agonists</searchLink><br />*<searchLink fieldCode="DE" term="%22GLUCAGON-like+peptide-1+receptor%22">GLUCAGON-like peptide-1 receptor</searchLink><br />*<searchLink fieldCode="DE" term="%22PEOPLE+with+diabetes%22">PEOPLE with diabetes</searchLink><br />*<searchLink fieldCode="DE" term="%22CARDIOVASCULAR+diseases%22">CARDIOVASCULAR diseases</searchLink> ) Array ( [Name] => SubjectGeographic [Label] => Geographic Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22SOUTH+Africa%22">SOUTH Africa</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Over four million people in South Africa are estimated to have diabetes. People diagnosed with diabetes have an increased risk of developing cardiovascular disease. Safety trials conducted on novel hypoglycaemic agents suggest that glucagon-like peptide-1 receptor agonists may afford cardiovascular benefits in this at-risk population. Selection of an agent from this class, as add-on treatment to metformin, should be individualised and based on accessibility, affordability, convenience of the dosing schedule, and tolerability. [ABSTRACT FROM AUTHOR] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 3
[StartPage] => 18
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => SOUTH Africa
[Type] => general
)
[1] => Array
(
[SubjectFull] => GLUCAGON-like peptide-1 agonists
[Type] => general
)
[2] => Array
(
[SubjectFull] => GLUCAGON-like peptide-1 receptor
[Type] => general
)
[3] => Array
(
[SubjectFull] => PEOPLE with diabetes
[Type] => general
)
[4] => Array
(
[SubjectFull] => CARDIOVASCULAR diseases
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The GLP-1 receptor agonists: what's all the (cardiovascular) hype about?
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Taylor, J.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mpofu, R.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Blockman, M.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Text] => Jan/Feb2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 22215875
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 90
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => SA Pharmaceutical Journal Incorporating Pharmacy Management
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |